Skip to main content
. 2022 Aug 19;207(2):160–172. doi: 10.1164/rccm.202110-2414OC

Figure 5.

Figure 5.

Fibroblast activation protein (FAP)-targeted positron emission tomography (PET)/computed tomography (CT) imaging of patients with interstitial lung disease (ILD). A total of 78 patients diagnosed as idiopathic pulmonary fibrosis (IPF) (n = 20), non-IPF ILD (n = 63), and healthy volunteers (n = 8) were recruited for a PET imaging study with 68Ga-FAPI-04. (A) The columns from left to right successively showed representative images of whole-body uptake for 68Ga-FAPI-04 with PET, 68Ga-FAPI-04 uptake in lung cross-section with CT, PET/CT, and the 68Ga-FAPI-04 total uptake with PET by three-dimensional (3-D) reconstruction. (B) Mean of standard uptake value (SUVmean) for 68Ga-FAPI-04 in all patients with ILD and healthy volunteers. The dashed line is a median. ****P < 0.0001. (C) Quantitative analysis for total volume uptake of PET tracer targeting FAP (SUVtotal) in different subtypes of patients with ILD and healthy volunteers. The dashed line is a median. **P < 0.01, ***P < 0.001, and ****P < 0.0001. (D) Correlation analysis between the uptake of 68Ga-FAPI-04 (SUVmean and SUVtotal) in ILDs (including patients with and without IPF) with KL-6, linear regression (r), and linear regression lines are plotted. P < 0.05 was considered statistically significant. ns = no significance.